Factors of Severity in Patients with COVID-19: Cytokine/Chemokine Concentrations, Viral Load, and Antibody Responses.
Factors of Severity in Patients with COVID-19: Cytokine/Chemokine Concentrations, Viral Load, and Antibody Responses.
复制标题
DOI:
10.4269/ajtmh.20-1110
复制
发表时间:
2020-12
期刊:
影响因子:
--
通讯作者:
Kim SH
中科院分区:
文献类型:
--
作者:
Kwon JS;Kim JY;Kim MC;Park SY;Kim BN;Bae S;Cha HH;Jung J;Kim MJ;Lee MJ;Choi SH;Chung JW;Shin EC;Kim SH
The severity of COVID-19 ranges from mild to critical diseases. However, limited data have been published on the detailed kinetics of viral load and host immune response throughout the disease course depending on disease severity. In this study, we comprehensively analyzed viral load, antibody responses to SARS-CoV-2, and cytokines/chemokines during the disease course, and identified the factors related to severity. Nasopharyngeal (NP) and plasma specimens were obtained from 31 patients with COVID-19 during hospitalization. Viral RNA in NP specimens was quantified by reverse transcription–PCR. Anti–SARS-CoV-2 antibodies and cytokines/chemokines in plasma specimens were analyzed by ELISA and cytometric bead array. The viral load in patients with COVID-19 peaked at the early stage of the disease and continuously decreased. Severe and critical cases showed higher viral load and prolonged viral shedding than asymptomatic and mild cases. Whereas plasma IgG was gradually increased and maintained during hospitalization, plasma IgM peaked at 3 weeks after symptom onset and dissipated. The antibody response in severe and critical cases was slightly delayed but stronger than those in others. High levels of interferon (IFN)-α, IFN-γ–induced protein-10, monokine induced by IFN-γ, and interleukin-6 at 5–10 days from symptom onset were associated with the severity of COVID-19. Our data indicate that high viral load in the respiratory tract and excessive production of cytokines and chemokines between 1 and 2 weeks from the symptom onset were significantly associated with the severity of COVID-19.
登录
查看更多内容
DOI:
10.1016/j.jcv.2018.01.017
发表时间:
2018-04
期刊:
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
影响因子:
--
作者:
Kwon JS;Kim MC;Kim JY;Jeon NY;Ryu BH;Hong J;Kim MJ;Chong YP;Lee SO;Choi SH;Kim YS;Woo JH;Kim SH
通讯作者:
Kim SH
DOI:
10.1056/nejmoa2022926
发表时间:
2020-11-19
期刊:
The New England journal of medicine
影响因子:
--
作者:
RECOVERY Collaborative Group;Horby P;Mafham M;Linsell L;Bell JL;Staplin N;Emberson JR;Wiselka M;Ustianowski A;Elmahi E;Prudon B;Whitehouse T;Felton T;Williams J;Faccenda J;Underwood J;Baillie JK;Chappell LC;Faust SN;Jaki T;Jeffery K;Lim WS;Montgomery A;Rowan K;Tarning J;Watson JA;White NJ;Juszczak E;Haynes R;Landray MJ
通讯作者:
Landray MJ
DOI:
10.15557/pimr.2020.0003
发表时间:
2020-01-01
影响因子:
3.6
作者:
通讯作者:
--
影响因子:
24.8
作者:
Lee, Jeong Seok;Park, Seongwan;Shin, Eui-Cheol
通讯作者:
Shin, Eui-Cheol
影响因子:
15.9
作者:
Wang, Yanqun;Zhang, Lu;Zhao, Jincun
通讯作者:
Zhao, Jincun